Literature DB >> 16695631

PENTAQUINE (SN-13,276), A THERAPEUTIC AGENT EFFECTIVE IN REDUCING THE RELAPSE RATE IN VIV AX MALARIA.

A S Alving1, B Craige, R Jones, C M Whorton, T N Pullman, L Eichelberger.   

Abstract

Entities:  

Year:  1948        PMID： 16695631      PMCID： PMC438886          DOI： 10.1172/JCI101957

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  8 in total

Review 1.  Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations.

Authors:  Hla Y Myint; Jonathan Berman; Larry Walker; Brandon Pybus; Victor Melendez; J Kevin Baird; Colin Ohrt
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

Review 2.  Chloroquine resistance in Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  Summary of antimalarial drugs.

Authors:  W C COOPER
Journal:  Public Health Rep       Date:  1949-06-10       Impact factor: 2.792

4.  The prisoner as model organism: malaria research at Stateville Penitentiary.

Authors:  Nathaniel Comfort
Journal:  Stud Hist Philos Biol Biomed Sci       Date:  2009-08-04

Review 5.  Determinants of relapse periodicity in Plasmodium vivax malaria.

Authors:  Nicholas J White
Journal:  Malar J       Date:  2011-10-11       Impact factor: 2.979

6.  PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites.

Authors:  Anne-Marie Zeeman; Suresh B Lakshminarayana; Nicole van der Werff; Els J Klooster; Annemarie Voorberg-van der Wel; Ravinder R Kondreddi; Christophe Bodenreider; Oliver Simon; Robert Sauerwein; Bryan K S Yeung; Thierry T Diagana; Clemens H M Kocken
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 7.  Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.

Authors:  Jonathan Berman; Tracey Brown; Geoffrey Dow; Stephen Toovey
Journal:  Malar J       Date:  2018-11-06       Impact factor: 2.979

8.  Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine.

Authors:  Pius S Fasinu; Babu L Tekwani; Bharathi Avula; Narayan D Chaurasiya; N P Dhammika Nanayakkara; Yan-Hong Wang; Ikhlas A Khan; Larry A Walker
Journal:  Malar J       Date:  2016-09-13       Impact factor: 2.979
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.